59 research outputs found
Dirac field on Moyal-Minkowski spacetime and non-commutative potential scattering
The quantized free Dirac field is considered on Minkowski spacetime (of
general dimension). The Dirac field is coupled to an external scalar potential
whose support is finite in time and which acts by a Moyal-deformed
multiplication with respect to the spatial variables. The Moyal-deformed
multiplication corresponds to the product of the algebra of a Moyal plane
described in the setting of spectral geometry. It will be explained how this
leads to an interpretation of the Dirac field as a quantum field theory on
Moyal-deformed Minkowski spacetime (with commutative time) in a setting of
Lorentzian spectral geometries of which some basic aspects will be sketched.
The scattering transformation will be shown to be unitarily implementable in
the canonical vacuum representation of the Dirac field. Furthermore, it will be
indicated how the functional derivatives of the ensuing unitary scattering
operators with respect to the strength of the non-commutative potential induce,
in the spirit of Bogoliubov's formula, quantum field operators (corresponding
to observables) depending on the elements of the non-commutative algebra of
Moyal-Minkowski spacetime.Comment: 60 pages, 1 figur
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty.In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding.A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1\%) in the rivaroxaban group and in 58 of 1558 patients (3.7\%) in the enoxaparin group (absolute risk reduction, 2.6\%; 95\% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2\%) in the rivaroxaban group and in 33 of 1678 patients (2.0\%) in the enoxaparin group (absolute risk reduction, 1.7\%; 95\% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3\%) in the rivaroxaban group and in 2 of 2224 patients (0.1\%) in the enoxaparin group (P=0.18).A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.
Urinary prothrombin fragment 1+2 in patients with venous thrombosis and myocardial infarction
<p>Patients with venous-thromboembolism (VTE) and myocardial infarction (MI) have elevated prothrombin fragment 1+2 (F1+2) levels. In patients with postoperative VTE, urinary F1+2 (uF1+2) was higher than in individuals without VTE. To explore the relationship between plasma and uF1+2 we performed a pilot study in patients with thrombotic events and healthy controls. In 40 patients with VTE or MI, and 25 age-and sex-matched healthy controls, F1+2 and D-dimer levels were measured in urine and plasma within 48 h after diagnosis. In addition, in all subjects renal function was assessed. Plasma and uF1+2 levels were positively correlated. Compared to controls, patients with VTE had higher levels of both plasma F1+2 (271 vs 160 pmol L-1, p <0.05) and uF1+2 levels (38 vs 28 pmol L-1), the latter, however, was not statistically significant. Patients with acute MI had similar F1+2 levels as controls in both plasma and urine. Differences in urinary F1+2 levels could not be attributed to differences in concentrations of creatinine or albumin in spot urine samples. Overall, D-dimer and F1+2 levels in urine were extremely low in all groups.</p>
EFFECTS OF VITAMINS AND NITROGEN SOURCES ON ASYMBIOTIC GERMINATION AND DEVELOPMENT OF ORCHIS LAXIFLORA AND OPHRYS SPHEGODES
Stickstofffunktionalisierung. Sauerstofffreie Plasmajet-Vorbehandlung für die Kunststoffaktivierung bei Umgebungsdruck
Cloning and DNA sequencing of bgaA, a gene encoding an endo-beta-1,3-1,4-glucanase, from an alkalophilic Bacillus strain (N137)
- …